Clinical trial
A Multi-center, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Neurological Effects of EryDex on Subjects With Ataxia Telangiectasia (NEAT)
NCT06193200 is registered in ClinicalTrials.gov with Quince Therapeutics S.p.A. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multi-center, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Neurological Effects of EryDex on Subjects With Ataxia Telangiectasia (NEAT)
- Lead sponsor
- Quince Therapeutics S.p.A.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- June 24, 2024
- Completion date
- December 17, 2025
- Enrollment
- 105 (actual)
- Sites
- 19
Conditions
As the registry lists them; a condition with its own page is linked.